Catheters and Active Implantable CDMO Market is predicted to reach USD 18.8 billion at a CAGR of 10.82% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Catheters and Active Implantable CDMO Market”.

The Global Catheters and Active Implantable CDMO Market is estimated to register a CAGR of 10.82% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the Global Catheters and Active Implantable CDMO Market - Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), Medeologix (Taiwan).

Market Highlights

The Global Catheters and Active Implantable CDMO Market is expected to register a CAGR of 10.82% during the forecast period and is estimated to reach USD 18.8 billion by 2032.

The Global Catheters and Active Implantable CDMO Market is emerging due to increasing strategic initiatives associated with catheters and active implantable CDMO and increased manufacturing outsourcing. Additionally, the growing geriatric population across the globe and facility expansion by contract development manufacturing organizations will provide growth opportunities for the market in the future.

Segment Analysis

The Global Catheters and Active Implantable CDMO Market has been segmented based on Service Category, and End-Users.

Based on the service segment, the global catheters and active implantable CDMO market has been differentiated into Catheters, Active Implantable Devices, and Endoscopy Devices. The catheters segment dominated the market in 2023, while the active implantable devices segment is projected to be the fastest-growing segment during the forecast period, 2024–2032.

The catheters are experiencing robust growth due to several key drivers. The increasing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and renal conditions necessitates the use of catheters for diagnosis and treatment. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 have diabetes, with nearly half unaware of the being diagnosed. According to IDF forecasts, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Active implantable catheters, which may include components like sensors or miniaturized electronics for real-time monitoring, demand high levels of expertise in both device design and manufacturing processes. For instance, Zeus Industrial Products, a specialist in advanced polymer solutions, has signed an agreement to integrate CathX Medical into its operations. CathX is a medical device contract manufacturer that provides companies a single source for catheter design engineering services, fast prototyping, production, and full or sub-assemblies.

On the basis of end user, the global catheters and active implantable CDMO market is segmented into medical device OEM companies, academic and research institutes, and government agencies. The medical device OEM companies segment dominated the market in 2023 and is projected to be the fastest-growing segment during the forecast period, 2024–2032.

Medical Device Original Equipment Manufacturers (OEMs) are crucial entities in the healthcare sector, responsible for the end-to-end development and production of medical devices. These companies play a pivotal role in transforming innovative concepts into market-ready products through comprehensive services that include design, prototyping, manufacturing, and regulatory compliance. Additionally, advancements in materials and global market expansion necessitate partnerships with CDMOs that offer innovative manufacturing techniques and can manage international standards. For instance, In January 2024, Germany based Sanner Group, a global healthcare packaging manufacturer and medical device contract development and manufacturing organization (CDMO), acquired Springboard, a design and development firm specialized in medical devices for regulated markets. The acquisition aligns with the company's goal of developing a portfolio of "world-leading services for customers across the drug-delivery, diagnostic, and medtech device sectors”.

Academic and research institutes are pivotal to the advancement of the medical device industry, serving as hubs of innovation and development. These institutions drive technological progress by conducting cutting-edge research, developing novel medical devices, and testing new concepts through rigorous clinical trials and laboratory evaluations. Additionally, Government agencies as end users of Contract Development and Manufacturing Organizations (CDMOs) specializing in active implantable medical devices engage in highly specialized partnerships to ensure the development and production of advanced, life-sustaining technologies.

Access Full Report @ https://www.marketresearchfuture.com/reports/catheters-active-implantable-cdmo-market-26788

Regional Analysis

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

Based on region, the Global Catheters and Active Implantable CDMO market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 6.43 billion by 2032, registering a CAGR of 9.59% during the forecast period.

North America accounted for the largest market share of 38.14% and is estimated to dominate the global Catheters and Active Implantable CDMO market. This large market share is due to technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge implantable devices drives the market. Furthermore, opportunities for expansion into emerging markets, the rise of personalized medicine, and the demand for minimally invasive solutions present avenues for growth. Moreover, strategic partnership and collaborations are fueling the demand for active implantable in North America. For instance, in December 2022, Veranex acquired Fusion Biotec, a company based in Orange, California that specializes in the design and engineering of complicated electromechanical diagnostic and medical equipment. The agreement brings together Veranex's infrastructure and quick development skills with Fusion's rapid concept-to-production capabilities, improving their focus on expediting diagnostic and medical technology solutions for regulatory and commercial success.

The Americas region is followed by Europe, marked by significant growth potential driven by technological advancements, and rising healthcare needs. Technological advancements in implantable devices—such as next-generation cardiac pacemakers, neurostimulators, and insulin pumps—are propelling demand for specialized manufacturing expertise. The increasing prevalence of chronic diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality implantable solutions.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors Rapid advancements in medical technology and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated implantable devices. The rising prevalence of chronic diseases, diabetes and an aging population further drive the need for innovative solutions.  For instance, according to National Institutes of Health (NIH), in Dec 2021, Diabetes accounts for approximately 80% of the worldwide disease burden, with Asia accounting for 60% of diabetics. Asia also has six of the top ten countries with the highest diabetes prevalence.

Key Findings of the Study

• The Global Catheters and Active Implantable CDMO Market is expected to reach USD 18.8 billion by 2032, at a CAGR of 10.82% during the forecast period.


• The North America Global Catheters and Active Implantable CDMO Market accounted for USD 2.64 billion in 2023 and is expected to exhibit a 9.59% CAGR during the forecast period.


• Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), Medeologix (Taiwan) are the key market players.